Jade Biosciences, Inc. (JBIO)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
22.85 USD
+0.97
(4.433%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 22.85 Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:35 a.m. EDT
The instrument is in a high-conviction technical recovery trend, snapping off the 200-day average, yet it remains a high-risk biotech value play with negative earnings and zero dividend sustainability despite a recent stock-based payout. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.071835 |
| AutoARIMA | 0.071837 |
| MSTL | 0.077877 |
| AutoTheta | 0.179863 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 56% |
| H-stat | 2.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.067 |
| Excess Kurtosis | -0.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2025-04-28 |
| Debt to Equity Ratio | 0.256 |
| Market Cap | 1,126,877,184 |
| Website | https://jadebiosciences.com |
As of April 19, 2026, 12:35 a.m. EDT: Options positioning shows significant put wall at the $7.5 strike, representing a major hedge or stop-loss level against further downside. However, call activity is concentrated in the Money (ITM), notably with $17.5 OMN calls holding the top Open Interest anchor, indicating support at current levels. There is a distinct lack of OTM call volume above the $20-$22 range, suggesting limited immediate speculative bias towards a rapid breakout, while the low ATM IV (0.9) implies low implied volatility expectations for near-term moves.
| Date | Dividend | Yield % |
|---|---|---|
| 2025-04-29 | 2.4 | 23.668638 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7643115 |
| Address1 | Building 23 |
| Address2 | Suite 105 221 Crescent Street |
| All Time High | 1,134.525 |
| All Time Low | 6.565 |
| Ask | 23.01 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 692,220 |
| Average Daily Volume3 Month | 429,151 |
| Average Volume | 429,151 |
| Average Volume10Days | 692,220 |
| Bid | 22.76 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 6.743 |
| City | Waltham |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.85 |
| Current Ratio | 21.091 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 23.335 |
| Day Low | 21.54 |
| Debt To Equity | 0.256 |
| Display Name | Jade Biosciences |
| Dividend Date | 1,745,798,400 |
| Earnings Timestamp | 1,772,803,800 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | -113,516,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.973 |
| Enterprise Value | 791,572,160 |
| Eps Trailing Twelve Months | -3.19 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.1577 |
| Fifty Day Average Change | 7.692301 |
| Fifty Day Average Change Percent | 0.50748473 |
| Fifty Two Week Change Percent | -76.43115 |
| Fifty Two Week High | 100.1 |
| Fifty Two Week High Change | -77.25 |
| Fifty Two Week High Change Percent | -0.7717283 |
| Fifty Two Week Low | 6.565 |
| Fifty Two Week Low Change | 16.285 |
| Fifty Two Week Low Change Percent | 2.480579 |
| Fifty Two Week Range | 6.565 - 100.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,059,800,000 |
| Float Shares | 32,432,856 |
| Free Cashflow | -61,348,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01364 |
| Held Percent Institutions | 1.01975 |
| Implied Shares Outstanding | 49,316,287 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,745,884,800 |
| Last Dividend Value | 2.4 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,745,884,800 |
| Last Split Factor | 1:35 |
| Long Business Summary | Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts. |
| Long Name | Jade Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,126,877,184 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1889513328 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -100,136,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,127,370,320 |
| Number Of Analyst Opinions | 7 |
| Open | 22.31 |
| Operating Cashflow | -94,689,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 781 312 3013 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 22.85 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 21.88 |
| Price Hint | 2 |
| Price To Book | 3.3886995 |
| Profit Margins | 0.0 |
| Quick Ratio | 20.325 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.970001 |
| Regular Market Change Percent | 4.43328 |
| Regular Market Day High | 23.335 |
| Regular Market Day Low | 21.54 |
| Regular Market Day Range | 21.54 - 23.335 |
| Regular Market Open | 22.31 |
| Regular Market Previous Close | 21.88 |
| Regular Market Price | 22.85 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 701,124 |
| Return On Assets | -0.33585998 |
| Return On Equity | -0.89185 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 49,316,287 |
| Shares Percent Shares Out | 0.0254 |
| Shares Short | 1,534,939 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,561,572 |
| Short Name | Jade Biosciences, Inc. |
| Short Ratio | 2.68 |
| Source Interval | 15 |
| State | MA |
| Symbol | JBIO |
| Target High Price | 40.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 28.71429 |
| Target Median Price | 24.0 |
| Total Cash | 336,158,016 |
| Total Cash Per Share | 6.816 |
| Total Debt | 851,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.825025 |
| Two Hundred Day Average Change | 11.024976 |
| Two Hundred Day Average Change Percent | 0.9323427 |
| Type Disp | Equity |
| Volume | 701,124 |
| Website | https://jadebiosciences.com |
| Zip | 2,453 |